Full-Time
Dialysis care technology with EMR integration
No salary listed
Boston, MA, USA
In Person
Willing to travel up to 75% of the time.
Bachelor's
| , |
See people who can refer or advise you
Outset Medical provides dialysis solutions by pairing the Tablo system with education and hands-on training for dialysis professionals. Tablo integrates with electronic medical records to streamline dialysis workflows, including charting and billing, and provides real-time treatment updates and alerts. They offer a Vascular Access Program to develop staff skills in cannulation and access management, plus a Bridge Program that helps facilities transition from outsourced dialysis to owning their own service line by supplying Outset nurses for 4–13 weeks. Revenue comes from Tablo sales and the accompanying training and support services, with the goal of improving dialysis care across hospitals, clinics, and home care by combining technology with staffing support.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Jose, California
Founded
2010
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, & vision
Life Insurance/AD&D
FSA & HSA
401k
Parental leave
Pet insurance
Tuition reimbursement
PTO
Company events
Outset Medical (NASDAQ:OM) CFO Renee Gaeta sells 4,543 shares of stock. August 18, 2026 Key points. * CFO Renee Gaeta sold 4,543 Outset Medical shares at an average price of $4.39, generating approximately $19,944. The sale covered tax-withholding obligations, leaving her with 180,840 shares. * Outset Medical shares fell to $4.18, while the company reported a quarterly loss of $0.80 per share, missing estimates, despite revenue of $31.64 million exceeding forecasts. * Analysts have a consensus "Hold" rating and a $10.00 price target, with three Buy ratings, one Hold, and one Sell rating. * Five stocks to consider instead of Outset Medical. Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CFO Renee Gaeta sold 4,543 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $4.39, for a total value of $19,943.77. Following the transaction, the chief financial officer owned 180,840 shares of the company's stock, valued at approximately $793,887.60. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Renee Gaeta also recently made the following trade(s): * On Wednesday, June 3rd, Renee Gaeta sold 17,672 shares of Outset Medical stock. The shares were sold at an average price of $4.94, for a total transaction of $87,299.68. Outset Medical stock performance. Shares of NASDAQ OM traded down $0.33 during midday trading on Tuesday, hitting $4.18. 143,860 shares of the company's stock were exchanged, compared to its average volume of 407,222. Outset Medical, Inc. has a twelve month low of $3.00 and a twelve month high of $16.16. The firm has a market cap of $78.57 million, a P/E ratio of -1.02 and a beta of 1.96. The stock's 50 day moving average price is $4.58 and its 200-day moving average price is $4.24. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11. Outset Medical (NASDAQ:OM - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. The company had revenue of $31.64 million for the quarter, compared to analyst estimates of $28.97 million. Equities research analysts anticipate that Outset Medical, Inc. will post -3.9 EPS for the current year. Hedge funds weigh in on Outset Medical. Several institutional investors and hedge funds have recently modified their holdings of OM. Los Angeles Capital Management LLC acquired a new position in Outset Medical in the fourth quarter worth approximately $29,000. Legal & General Group Plc acquired a new stake in Outset Medical in the second quarter valued at approximately $34,000. BNP Paribas Financial Markets grew its position in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company's stock worth $40,000 after acquiring an additional 2,034 shares in the last quarter. Hsbc Holdings PLC bought a new stake in Outset Medical in the fourth quarter worth approximately $46,000. Finally, HRT Financial LP acquired a new position in shares of Outset Medical during the 4th quarter worth $58,000. Analysts set new price targets. OM has been the topic of several research reports. TD Cowen reaffirmed a "buy" rating on shares of Outset Medical in a report on Friday, May 8th. Weiss Ratings upgraded Outset Medical from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 7th. Finally, Wall Street Zen raised Outset Medical from a "sell" rating to a "hold" rating in a research report on Saturday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Outset Medical currently has an average rating of "Hold" and a consensus target price of $10.00. Discover more Stock Screener Tool Options Profit Calculator About Outset Medical. Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy. Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long-term care facilities and emergency response scenarios. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Outset Medical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outset Medical wasn't on the list. While Outset Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
Outset Medical reported second-quarter 2026 revenue of $31.6 million, up 1% year-over-year and 14% sequentially. The dialysis technology company's non-GAAP gross margin improved to 42.2%, up over 380 basis points from the previous year. The company secured a $40 million refresh agreement with HCA Healthcare extending through 2028, providing enhanced revenue visibility. Product revenue declined 5% year-over-year to $21.9 million, whilst service and other revenue grew 17% to $9.7 million. Outset completed its highest number of new site implementations in several years. One Texas system trained over 100 nurses and supported 956 treatments in the first 60 days. The company ended the quarter with $151 million in cash and reiterated full-year 2026 revenue guidance of $125 million to $130 million. It expects to use less than $40 million in cash for the full year.
Outset Medical, Inc. (NASDAQ: OM) investor alert: possible false statements, over $50 million in insider sales. Classactionlawyers advise Outset Medical, Inc. (NASDAQ: OM) investors that the firm is investigating potential legal claims arising from alleged false statements about FDA clearance requirements for one of the company's key products and demand for its dialysis machines. On March 30, 2026, U.S. District Judge Edward J. Davila ruled that key claims in a securities fraud lawsuit against Outset Medical and its CEO and former CFO will move forward. The lawsuit alleges that between September 2020 and August 2024, the company misled investors by describing TabloCart as a non-medical accessory and later touting customer demand for Tablo dialysis systems, despite knowing that TabloCart required clearance from the U.S. Food and Drug Administration and that demand for Tablo was weakening. These statements allegedly caused Outset Medical's stock to trade at artificially inflated prices. Judge Davila found the complaint sufficiently alleged that defendants acted with scienter, or an intent to deceive, in making these false and misleading statements. During this period, company insiders sold over $50 million in stock. After the full truth came out in August 2024, when the company reported disappointing second quarter 2024 results, the stock price fell 68%. Classactionlawyers is investigating potential wrongdoing by Outset Medical's directors and officers in connection with these allegations. If you own Outset Medical stock and wish to obtain additional information about your legal rights, please fill out the form below.
Outset Medical reported Q1 revenue of $27.9 million, down slightly year-over-year due to capital order timing, but reaffirmed full-year guidance of $125–$130 million with growth expected in Q3 and Q4. Product revenue fell 13% to $18.6 million, whilst consumable sales reached $13.2 million and service revenue rose 10% to $9.3 million. Non-GAAP gross margin improved 620 basis points to 43.8% and non-GAAP net loss narrowed to $15.4 million. The company ended the quarter with $161 million in cash and now expects full-year cash usage below $40 million. Management plans a limited release of its next-generation Tablo dialysis system in Q2 through Q3, followed by a full launch. The system will be the first cleared under the FDA's 2025 cybersecurity requirements.
Outset Medical has granted equity awards to two new employees under its Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The medical technology company awarded 96,000 restricted stock units to Derick Elliott, newly appointed Executive Vice President of Commercial, and 10,380 RSUs to another non-executive employee. The RSUs will vest over three years, with 33.33% vesting on the one-year anniversary of each employee's start date and the remaining 66.67% vesting quarterly thereafter, subject to continued service. Outset Medical develops the Tablo Hemodialysis System, which is used by over 1,000 US healthcare facilities. The company aims to reduce the cost and complexity of dialysis through integrated technology that combines water purification and dialysate production.